NCT05930457 - Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors | Biotech Hunter

Enrollment

15

Participants

Timeline

Start Date

July 26, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

December 18, 2023

Conditions

Malignant Solid Tumors

Interventions

DRUG

2.5-3.5mCi 64Cu-FAPI-XT117

64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 2.5-3.5mCi 64Cu-FAPI-XT117 injection.

DRUG

3.5-4.5mCi 64Cu-FAPI-XT117

64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 3.5-4.5mCi 64Cu-FAPI-XT117 injection.

DRUG

4.5-5.5mCi 64Cu-FAPI-XT117

64Cu-FAPI-XT117 and 18F-FDG PET/CT were performed for each patient(the interval was more than one day and less than four weeks). PET/CT images were acquired 30min, 60min, 120min after 4.5-5.5mCi 64Cu-FAPI-XT117 injection.

Trial Locations (1)

Unknown

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou